Generic Zetonna Availability

Zetonna is a brand name of ciclesonide nasal, approved by the FDA in the following formulation(s):

ZETONNA (ciclesonide - aerosol, metered;nasal)

  • Manufacturer: TAKEDA GMBH
    Approval date: January 20, 2012
    Strength(s): 0.037MG/INH [RLD]

Has a generic version of Zetonna been approved?

No. There is currently no therapeutically equivalent version of Zetonna available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zetonna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
    Patent 5,482,934
    Issued: January 9, 1996
    Inventor(s): Calatayud; Jose & Conde; Jose R. & Luna; Manuel
    Assignee(s): Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.)
    The present invention relates to compounds of the formula: ##STR1## in which X.sub.1 and X.sub.2 correspond to H or F without distinction; R.sub.1 represents the following radicals: ##STR2## and R.sub.2 represents the radicals ##STR3## in the form of an R epimer, an S epimer, or a stereoisomeric mixture of the R and S epimers in terms of the orientation of the substituents on the carbon atom at position 22, novel intermediates and a method of their preparation by hydrolysis-ketalization, and use of such compounds as drugs and/or therapeutic agents.
    Patent expiration dates:
    • October 24, 2017
      ✓ 
      Patent use: METHOD OF TREATING INFLAMMATORY CONDITIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Medicinal aerosol formulations
    Patent 5,605,674
    Issued: February 25, 1997
    Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
    Assignee(s): Riker Laboratories, Inc.
    A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Patent expiration dates:
    • February 25, 2014
      ✓ 
      Drug product
  • Medicinal aerosol formulations
    Patent 5,683,677
    Issued: November 4, 1997
    Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
    Assignee(s): Riker Laboratories, Inc.
    A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Patent expiration dates:
    • November 4, 2014
      ✓ 
      Drug product
  • Seal configuration for aerosol canister
    Patent 5,775,321
    Issued: July 7, 1998
    Inventor(s): Alband; Todd D.
    Assignee(s): Minnesota Mining and Manufacturing Company
    A dual seal configuration for an aerosol canister containing a medicinal aerosol formulation. The canister includes a vial body and valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation. The dual seal configuration reduces leakage of contents, and is particularly helpful where the formulation includes hydrofluorocarbon propellant and an ethanol cosolvent. The first seal can be selected to be a barrier to the formulation components, while the second seal can be relatively more labile to such components.
    Patent expiration dates:
    • July 7, 2015
      ✓ 
      Drug product
  • Device for delivering an aerosol
    Patent 6,006,745
    Issued: December 28, 1999
    Inventor(s): Marecki; Paul E.
    Assignee(s): Minnesota Mining and Manufacturing Company
    A device for delivering an aerosol comprises a casing member, a valve stem, and a sealing member, wherein the sealing member comprises a thermoplastic elastomer comprising of a copolymer of about 80-95 mole % ethylene and about 5-20 mole % of at least one comonomer wherein the comonomer(s) are 1-butene, 1-hexene, or 1-octene. The device is used with pharmaceutical formulations containing 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane as the propellant.
    Patent expiration dates:
    • December 28, 2016
      ✓ 
      Drug product
  • Medicinal aerosol products containing formulations of ciclesonide and related steroids
    Patent 6,120,752
    Issued: September 19, 2000
    Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
    Assignee(s): 3M Innovative Properties Company Byk Gulden Lomberg Chemische Fabrik GmbH
    A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Patent expiration dates:
    • May 13, 2018
      ✓ 
      Drug product
  • Medicinal aerosol formulation of ciclesonide and related compounds
    Patent 6,264,923
    Issued: July 24, 2001
    Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
    Assignee(s): 3M Innovative Properties Company
    A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Patent expiration dates:
    • May 13, 2018
      ✓ 
      Drug product
  • Use of ciclesonide for the treatment of respiratory diseases
    Patent 8,371,292
    Issued: February 12, 2013
    Assignee(s): Nycomed GmbH
    The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.
    Patent expiration dates:
    • August 25, 2027
      ✓ 
      Patent use: TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 20, 2015 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)